retatrutide fda approval timeline 2025 Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Retatrutide: The Unapproved Drug America

The question has shifted from "is it too expensive to cover GLP-1?" to "is it too expensive not to?" As clinical data accumulates showing that GLP-1 medications reduce the incidence and severity of the most expensive chronic diseases, payers are recognizing that proactive treatment of obesity saves money compared to treating its downstream consequences

306 For example, the reduction in TNF-, IL-1, and IL-6 helps regulate local and systemic inflammatory responses

Severe dehydration can lead to dizziness, weakness, kidney injury, low blood pressure, electrolyte imbalance, cardiac complications, and hospitalization requiring intravenous fluids or nutritional support

In midlife care, the sequence of intervention often determines the sustainability of results